Bridge Bio Pharma, Inc. BBIO
We take great care to ensure that the data presented and summarized in this overview for BridgeBio Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BBIO
View all-
Viking Global Investors LP22.1MShares$1.01 Billion2.55% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY19.3MShares$886 Million30.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.9MShares$685 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$572 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.17MShares$330 Million0.14% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$279 Million73.33% of portfolio
-
State Street Corp Boston, MA5.75MShares$264 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA5.73MShares$264 Million1.14% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.67MShares$215 Million0.04% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.8MShares$175 Million8.27% of portfolio
Latest Institutional Activity in BBIO
Top Purchases
Top Sells
About BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Insider Transactions at BBIO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 02
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-1.23%
|
$1,680,000
$42.73 P/Share
|
Jul 01
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.61%
|
$1,680,000
$42.7 P/Share
|
Jun 27
2025
|
Viking Global Investors LP |
SELL
Open market or private sale
|
Indirect |
3,500,000
-15.87%
|
$154,000,000
$44.0 P/Share
|
Jun 27
2025
|
Charles J Homcy |
SELL
Bona fide gift
|
Direct |
20,000
-1.62%
|
-
|
Jun 26
2025
|
Hannah Valantine |
SELL
Open market or private sale
|
Indirect |
2,289
-48.71%
|
$100,716
$44.08 P/Share
|
Jun 26
2025
|
Hannah Valantine |
SELL
Open market or private sale
|
Direct |
2,418
-12.99%
|
$106,392
$44.06 P/Share
|
Jun 24
2025
|
Frank Mccormick |
SELL
Open market or private sale
|
Indirect |
100,000
-10.2%
|
$4,400,000
$44.23 P/Share
|
Jun 20
2025
|
Jennifer E. Cook |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+32.41%
|
-
|
Jun 20
2025
|
Andrea Ellis |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+26.17%
|
-
|
Jun 20
2025
|
Andrew Lo |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+10.75%
|
-
|
Jun 20
2025
|
Ali J. Satvat |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+3.82%
|
-
|
Jun 20
2025
|
Ronald J Daniels |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+27.94%
|
-
|
Jun 20
2025
|
Eric Aguiar |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+50.0%
|
-
|
Jun 20
2025
|
Frank Mccormick |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+98.76%
|
-
|
Jun 20
2025
|
Hannah Valantine |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+44.1%
|
-
|
Jun 20
2025
|
Douglas A. Dachille |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+50.0%
|
-
|
Jun 20
2025
|
Fred Hassan |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+20.29%
|
-
|
Jun 20
2025
|
Charles J Homcy |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+0.53%
|
-
|
Jun 20
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+6.48%
|
-
|
Jun 20
2025
|
Randal W. Scott |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+36.25%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 287K shares |
---|---|
Exercise of conversion of derivative security | 602K shares |
Bona fide gift | 4.69M shares |
Open market or private sale | 25.8M shares |
---|---|
Bona fide gift | 4.75M shares |
Payment of exercise price or tax liability | 228K shares |